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Topical drug deliveryThe treatment of onychomycosis remains problematic even though there are several potent antifungal
agents available for patient use. The aim of this investigation was to understand whether the structural
modifications that arise when a patient’s nail become infected plates influences the permeation of drugs
into the nail following topical application. It was hoped that through improving understanding of the nail
barrier in the diseased state, the development of more effective topical treatments for onychomycosis
could be facilitated. The permeation of three compounds with differing hydrophobicities, caffeine, terbi-
nafine and amorolfine (clogD at pH 7.4 of 0.55, 3.72 and 4.49 respectively), was assessed across both
healthy and onychomycosis infected, full thickness, human nail plate sections. Transonychial water loss
(TOWL) measurements performed on the healthy and diseased nails supported previous observations
that the nail behaves like a porous barrier given the lack of correlation between TOWL values with the
thicker, diseased nails. The flux of the more hydrophilic caffeine was twofold greater across diseased
in comparison with the healthy nails, whilst the hydrophobic molecules terbinafine and amorolfine
showed no statistically significant change in their nail penetration rates. Caffeine flux across the nail
was found to correlate with the TOWL measurements, though no correlation existed for the more
hydrophobic drugs. These data supported the notion that the nail pores, opened up by the infection, facil-
itated the passage of hydrophilic molecules, whilst the keratin binding of hydrophobic molecules meant
that their transport through the nail plate was unchanged. Therefore, in order to exploit the structural
changes induced by nail fungal infection it would be beneficial to develop a small molecular weight,
hydrophilic antifungal agent, which exhibits low levels of keratin binding.
 2016 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Onychomycosis is a fungal infection of the nail that accounts for
approximately 50% of all nail disorders and affects toenails consid-
erably more often than fingernails [1,2]. The prevalence of ony-
chomycosis has been estimated at around 5% in Western
countries and has continued to increase in recent decades [3–9].
It is important to treat onychomycosis as it is an infection that does
not resolve spontaneously, and it may cause pain and can substan-
tially reduce the quality of life of patients [10,11]. In addition, if left
untreated the infection may worsen, spread to other uninfected
locations (other nails or to the surrounding skin) or infect other
patients. This is especially true for immunocompromised patientsand diabetics where the infection can cause major complications
[11]. Although, at present, nail removal and oral administration
of antifungals are the most effective options for the treatment of
onychomycosis, their cost, as well as the toxicity and drug interac-
tions associated with oral drug therapy [12–14] means that direct
application of a therapeutic agent to the nail plate is the most pop-
ular approach with clinicians and patients.
A number of topical treatments are currently licensed for ony-
chomycosis and the local application of these products does not
carry the risks of serious side effects (such as hepatotoxicity) asso-
ciated with systemic antifungals and they are less painful than full
or partial nail removal. However, all of the topical products require
repetitive re-application over long treatment times (e.g. 12 months
for toenail infections) [15]. One approach to potentially reduce the
treatment time is to enhance drug penetration through the nail
plate. The provision of a sufficient amount of the antifungal should
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chomycosis therapy is excellent, however the biopharmaceutical
problem of improving xenobiotic penetration through the nail
plate is not easy to address due to the effective barrier properties
of the nail [16–23].
One reason why so little is known about the onychomycotic nail
is that there is not a suitable pre-clinical animal model that can be
used to validate new formulations prior to their use in patients.
This has led to the majority of formulation development and nail
characterisation being performed in vitro or ex vivo using healthy
human nails [24–26]. The availability of diffusion chambers that
can hold very small cross sections of nail tissue has now made it
possible to try and address the dearth of information on the struc-
ture and properties of fungally-infected nail plates. These cham-
bers have recently demonstrated that onychomycotic nail plate
infection obtained in vivo, which increased the nail plate thickness
and porosity and reduced its tensile strength and density without
disrupting disulphide bonding and/or desmosomes, increased nail
permeability when an aqueous vehicle was applied to the nails api-
cal surface [27]. The conclusion that the onychomycotic nail was
more permeable than healthy human nail tissue was in agreement
with the only other published study in this field [28], but more
data were required to understand whether this increase in nail per-
meability could be exploited by traditional antifungal agents which
are normally more hydrophobic than the molecules used in the
preliminary work. Hence, the aim of this study was to further
investigate the permeability of infected nails using an ex vivo nail
model that employed onychomycosis infected patient’s nail using
two anti-onychomycotic drugs with differing physicochemical
properties (terbinafine and amorolfine; logD pH 7.4 values of
3.72 and 4.49 and molecular weights of 328 and 354 respectively)
and compare this with a hydrophilic model drug caffeine (logD pH
7.4 of 0.55, molecular weight 194). It was anticipated that by
challenging the nail barrier with these three molecules in order
to understand how the differing barrier function of diseased nail
plate affect the ungual absorption, new strategies to improve the
topical treatment of onychomycosis could be developed. To
achieve this the ChubTurTM cell was used to determine drug pene-
tration into the nail [26,27,29] and the nail barrier was charac-
terised using TOWL.2. Materials and methods
2.1. Materials
Calibrated ChubTur diffusion cells were kindly loaned by Med-
Pharm Ltd (Guildford, UK). Tetrahydrofuran was purchased from
Acros Organic (Geel, Belgium). Terbinafine HCl and Amorolfine
HCl were provided by TCI (Oxford, UK) and Caffeine by Sigma–
Aldrich (Dorset, UK). Fisher Scientific (Leicester, UK) supplied tri-
ethylamine, orthophosphoric acid, acetonitrile, absolute ethanol,
sulphuric acid, propan-2-ol, glacial acetic acid and sodium acetate.
Phosphate buffer saline tablets were purchased from Oxoid
(Hampshire, UK).2.2. Nail clippings: collection and storage
Healthy nail clippings were collected from volunteers (REC/
B/10/01 School of Pharmacy Ethics Committee, University of Lon-
don). Diseased nail samples were supplied by podiatrists and der-
matologists (ethics approval, PHAEC/09-24, School of Pharmacy
Ethics Committee of the School of Pharmacy, University of Hert-
fordshire and ethics approval, 12/YH/0381, NRES Committee York-
shire & The Humber – Sheffield). The procedures employed for the
storage of healthy and diseased nail clippings were developed witha view to retaining the nail in its natural state prior to analysis. For
healthy nail clippings, removal of all dirt and debris and washing
with water prior to storage were adopted to remove any surface
contaminants that could influence the analytical tests. These two
stages are associated with everyday cleaning of nails in vivo and
therefore cleaning by removal of debris and washing with water
were not expected to introduce any significant change in the
healthy samples. Healthy nails were kept in sealed polyethylene
bags at room temperature prior to use. Diseased nails were kept
in sealed vials at 4 C as this temperature does not affect fungi via-
bility [30] but it inhibits its growth. Nail dimensions were taken
using a micrometer (RS components, Corby, UK) and were con-
ducted at room temperature at ambient relative humidity (40–
60%).
2.3. Transonychial water loss measurement (TOWL)
Nail pieces were trimmed to approximately 3  3 mm and the
width, breadth and thickness of the nail samples were measured
with a micrometre as aforesaid. The nail sections were then
clamped and held in place between the receiver and donor cham-
bers of calibrated ChubTur diffusion cells, as described previously
[26]. The dorsal area exposed to the donor chamber was
0.0314 cm2. The receiver chambers of each cell were filled with
deionised water and a stirring bar was introduced. The receiver
fluid of each cell was briefly degassed by sonication and the cells
were inverted to remove the resulting air bubble from the ventral
face of the nail clipping. The nail clippings were initially left in the
calibrated ChubTur diffusion cells for 24 h to allow the nail sam-
ples to hydrate and reach steady state. The condenser-chamber
AquaFlux AF200 (Biox Systems Ltd., London, UK) was then used
to measure transonychial water loss (TOWL). Each recorded TOWL
measurement was determined over a 5 min period and if this
showed a typical and reproducible water vapour density curves
over this time the cells were used for the permeation studies. In
contrast, any setup that showed an atypical water vapour density
curves such as no transient peak or extensively long equilibration
times to the steady state TOWL value was rejected. After successful
completion of the TOWL measurement, each cell was emptied and
left to dry prior to conducting drug permeation studies.
2.4. Permeation studies
Both healthy and diseased nails were mounted in ChubTurTM dif-
fusion cells which were used for the permeation studies. The recei-
ver chambers of each cell were filled with relevant receiver fluid
and a stirring bar was introduced. For caffeine the receiver fluid
was PBS pH 7.2, and for terbinafine and amorolfine it was PBS
pH 7.2/Ethanol (1:1, v/v). These fluids were chosen to ensure ade-
quate solubility of the drug and that sink conditions were always
maintained in the receiver fluid throughout the permeation exper-
iments. For comparative purposes, approximately 44% and 20% of
terbinafine (pKa 7.1) and amorolfine (pKa 6.6) would be expected
to be ionised respectively in an aqueous environment at pH 7.2.
In contrast caffeine (pKa 0.6) would be expected to be unionised.
The stability of each drug in the receiver fluid was also confirmed
(data not shown). As before with the TOWL experiments, the recei-
ver fluid of each cell was briefly degassed by sonication and the
cells were inverted to remove the resulting air bubble from the
ventral face of the nail clipping. The receiver chamber was then
sealed with Parafilm and the receiver fluid of diffusion cells was
then stirred and acclimatised overnight in a water bath maintained
at 37 C, which provided a nail surface temperature of 32 C. Satu-
rated solutions of caffeine, terbinafine and amorolfine were pre-
pared by incubating and stirring an excess of solid for 24 h in
their respective receiver fluid. The saturated solutions were
Fig. 1. Permeation profiles of caffeine across healthy (d) and diseased (N) nail
samples. Data are shown as the mean ± SD.
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5 mL) so that the level of the penetrant solution aligned with that
of the side arm of the receiver chamber. The donor chambers were
then sealed with Parafilm for the duration of the experiment to
prevent evaporation of donor solutions after which the receiver
fluid was sampled at predetermined time points. At each time
point and before sampling, the cells were visually inspected and
inverted 3 times. Replicate experiments were performed for each
drug with n = 5–7 for the caffeine experiments and n = 11–13 and
13–15 for the amorolfine and terbinafine experiments respectively.
2.5. HPLC analysis
The amount of caffeine, terbinafine and amorolfine in the sam-
ples was quantified by a dual pump Agilent Technologies Infinity
1260 high performance liquid chromatography (HPLC) system
(Agilent, Stockport UK) equipped with an autosampler and con-
nected to a UV/Vis detector. This system was connected to a PC
with Agilent ChemStation software for data acquisition and collec-
tion. The HPLC methods used for each drug were adapted from
those kindly provided by MedPharm Ltd (Guildford, UK). For the
quantification of caffeine an Agilent Zorbax Eclipse Plus C18 HPLC
column, 150  4.60 mm 3.5 lm was used in conjunction with an
Agilent Reliance Guard column hardware kit containing an Agilent
ZORBAX Reliance C18 4.6  22.5 mm cartridge. The injection vol-
ume was 10 lL. An isocratic method was used with a mobile phase
composition of sodium acetate buffer (pH 4.5)/acetonitrile/
tetrahydrofuran 95.5/2.5/2 (v/v/v). The flow rate of the mobile
phase was 1 mL/min, the column temperature was 23 C and the
UV detection wavelength was 275 nm. The retention time of caf-
feine under these conditions was 8.9 min.
For terbinafine quantification a Phenomenex Luna C18(2)
100A 150  2.00 mm 5 lm HPLC column (Phenomenex, Maccles-
field, UK) was used in conjunction with a Phenomenex Security
Guard Column holder containing a C18 4  2 mm cartridge. The
injection volume was 10 lL. Again an isocratic method was used
with a mobile phase composition of orthophosphoric acid and tri-
ethylamine buffer (pH 2.5)/Acetonitrile 60/40 (v/v). The flow rate
of the mobile phase was 0.3 mL/min, the column temperature
was 23C and the UV detection wavelength was 224 nm. The reten-
tion time of terbinafine under these conditions was 7.1 min. The
same specification of HPLC and guard columns as was used for
the analysis of terbinafine concentrations was used to quantify
amorolfine. Again an isocratic method was used, however the
mobile phase composition was adjusted to 55/45 (v/v) orthophos-
phoric acid and triethylamine buffer (pH 2.5)/acetonitrile. The flow
rate of the mobile phase was 0.3 mL/min, the column temperature
was 23 C and the UV detection wavelength was 219 nm. The HPLC
methods were validated for linearity, precision and accuracy
according to the current ICH guidelines with correlation coefficient
(R2) values greater than 0.999, accuracy values of 100 ± 2% and rel-
ative standard deviation values (RSD) of less than 2% for both
repeatability and precision measurements for all three drugs
[31,32].
2.6. Data analysis
The cumulative amounts of drug penetrating the nail per unit
surface area (lg/cm2) were corrected for previous sample removal
and plotted against time (h). The slope of the linear portion of the
permeation profile (R2 > 0.95) was estimated as the pseudo steady-
state flux (Js) of penetrant permeation. The lag times (L) for each
drug were derived from the x-intercept of the slope at pseudo
steady-state and used to provide as estimate of the diffusion coef-
ficients (D) of the drugs, with D being calculated as D = h2/6Lwhere
h is the nail thickness. The permeability coefficients (Kp) of eachdrug were calculated as drug flux/drug concentration in the donor
chamber. The results were expressed as mean ± standard deviation
(SD) and were statistically analysed with IBM SPSS software. Data
were tested to determine whether they were normally distributed
or not and then analysed using either a t-test or nonparametric
Mann–Whitney U test for parametric and nonparametric data
respectively. For multiple comparisons, ANOVA was used with post
hoc analysis performed with Tukey’s test. Pearson correlation was
used to examine the relationship between parameters measured in
the study. Statistical significance was accepted at the p 6 0.05
level.3. Results and discussion
3.1. Nail permeation
The permeation profiles of caffeine, terbinafine and amorolfine
across health and diseased nails are shown in Figs. 1–3 respec-
tively. The lengthy lag period prior to a linear increase in the cumu-
lative amount of drug permeated in these infinite dose
experiments is typical of nail permeation experiments [33]. The
length of the lag time makes analysis of the data using Fick’s first
law of diffusion difficult as steady state flux should be measured
from approximately 2.7 times past the lag time [34]. Nonetheless
the linear portions of the graph can be used to provide estimates
of, or ‘pseudo’ steady state flux and allow estimation of lag times.
Table 1 displays the permeation parameters calculated for each of
the drugs across healthy and diseased nails along with thickness of
the nails used in the experiments.
The diseased nail plates, sourced from the patient volunteers,
were thicker than their healthy equivalents (Table 1). Onychomy-
cosis increases the nail plate thickness when the disease is
acquired in vivo [27]; therefore, this difference in nail tissue thick-
nesses across the two different patient groups was considered
unavoidable. As a consequence the subsequent results are dis-
cussed with relation to this disparity in the diffusion barrier thick-
ness where it was felt important to the study’s conclusions. The
study’s data interpretation was not further complicated by any dis-
crepancy across the thicknesses of the tissues employed for each of
the three drugs beyond that which has already been mentioned, i.e.
both the health and diseased groups of nails used for the caffeine,
terbinafine and amorolfine experiments were not statistically dif-
ferent across the three drug types (ANOVA, p > 0.05).
The disease state had a large influence of the permeation pro-
files and parameters of caffeine, with the in vitro flux, lag time, dif-
fusion coefficient and maximum quantity of caffeine permeating
through the nail all being significantly different for healthy and
diseased nails (p < 0.05, t-test) (Fig. 1 and Table 1). The mean
Fig. 2. Permeation profiles of terbinafine across healthy (d) and diseased (N) nail
samples. Data are shown as the mean ± SD.
Fig. 3. Permeation profiles of amorolfine across healthy (d) and diseased (N) nail
samples. Data are shown as the mean ± SD.
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maximum amount of drug that permeated through diseased nails
were more than double the corresponding values for the healthy
nails, whilst the lag time was approximately 1.5 times shorter. In
contrast to caffeine, terbinafine and amorolfine nail permeation
showed negligible differences between healthy and diseased nails
(Figs. 2 and 3 and Table 1) for the drug flux, permeability coeffi-
cient and total quantity of drug permeated. When the data were
normalised to account for the greater thickness of the diseased
nails, differences in the diffusion co-efficient were obtained, with
higher values being obtained for diseased nails (t test, p < 0.05).
However as the changes in nail anatomy are inherent to the dis-
ease, the permeation data conclusions were drawn from the data
which were not corrected in terms of nail thickness, as this was
thought to be a better representation of the challenges faced by
real products in vivo. The presence of ethanol in the receiver fluidTable 1
TOWL and thickness of the healthy and diseased nails used in the permeation experiments
caffeine, terbinafine and amorolfine. Data are shown as the mean ± SD.








Caffeine Healthy 0.5 ± 0.1 9.7 ± 2.3 3.07 ± 0.86
Diseased 0.7 ± 0.1 10.6 ± 1.8 6.56 ± 1.11
Terbinafine Healthy 0.5 ± 0.1 13.3 ± 3.0 0.41 ± 0.30
Diseased 0.8 ± 0.2 13.3 ± 1.5 0.55 ± 0.66
Amorolfine Healthy 0.5 ± 0.1 12.6 ± 1.0 0.89 ± 0.36
Diseased 0.9 ± 0.1 12.8 ± 1.1 0.89 ± 0.40and donor suspension for both terbinafine and amorolfine was nec-
essary given the low aqueous solubility of both drugs. However its
inclusion was not thought likely to alter the nature of the differ-
ences between healthy and diseased nails and so the comparison
of the data with that of caffeine where ethanol was not present
was considered valid for comparison of permeation across healthy
and diseased samples.
When the three permeant molecules were compared with one
another, drug flux was highest and lag time was the shortest for
caffeine through both healthy and diseased nail plates (ANOVA,
post hoc Tukey, p < 0.05) whilst there were no statistical differ-
ences between the respective values for terbinafine and amorolfine
(ANOVA, post hoc Tukey, p > 0.05). Obtaining the highest ungual
flux with the smallest, most hydrophilic molecule, caffeine (MW
194), through both healthy and diseased nails correlates with the
notion that the human nail plate can be considered as a porous
barrier which is amenable to penetration by hydrophilic xenobi-
otics [35,36]. Previous studies have shown that it is highly prob-
lematic to isolate the effects of the two important
physicochemical properties that influence nail penetration, i.e.
molecular weight and hydrophobicity, and the data presented in
this study do not attempt to make any claims regarding the relative
importance of these molecular characteristics; this has been dis-
cussed by previously published studies [28,37]. Rather, it appears
more appropriate to use the data from the current study to support
the previously purported notion that the nail is a hydrophilic gel
membrane, which favours the permeation of water-soluble com-
pounds [20,37]. This is because the caffeine (MW 194, calculated
logD of 0.55) nail penetration, like fluorouracil (MW 130; logD
at pH 4 of 0.96) [28,38], penetrated through the diseased nail bar-
rier, which has a greater porosity [27], more rapidly, whilst the two
hydrophobic antifungal drugs showed little change in permeation
parameters. This is in agreement with results obtained by Nair
et al. who found terbinafine permeation across onychomycosis
infected human nail to not be significantly different to previously
published work across healthy nail tissue [39]. Overall this type
of behaviour is typical of gels that swell in response to hydration
to a certain point, influencing their penetrability by polar mole-
cules, but not by hydrophobic agents that have a tendency to
adsorb the gel. This may explain why the effects of permeant
lipophilicity on nail permeation are not so well understood. When
previous investigations have used an homologous series of com-
pounds, e.g., n-alkanols and p-hydroxybenzoic esters to under-
stand the effect of lipophilicity on nail permeation, they have
assumed that the nail is a highly confluent barrier like the skin
[22,37]. This theoretical basis seemed to drive the previous sugges-
tions of Walters and coworkers that there was a lipidic pathway
through the nail plate which allowed a greater permeation of
decanol and dodecanol, compared to lower alcohols (C3–C8)
[22,23]. However, more recent work, which showed no enhance-
ment of nailplate permeability to terbinafine upon defatting (incu-
bation in chloroform: methanol 2:1 mixture for 12 h), implied thatalong with the drug flux, diffusion coefficient and total drug quantity permeated for








121.5 ± 33.2 3.5 ± 0.9 17.6 ± 4.9 460.3 ± 220.3
84.3 ± 16.1 8.8 ± 1.8 37.7 ± 6.4 1211.8 ± 271.0
339.8 ± 115.3 1.6 ± 0.9 7.1 ± 5.2 149.8 ± 123.0
327.6 ± 98.2 3.7 ± 2.0 9.5 ± 11.4 228.1 ± 311.3
299.8 ± 37.1 1.4 ± 0.4 1.6 ± 0.6 390.9 ± 154.3
284.3 ± 14.6 4.5 ± 1.3 1.6 ± 0.7 416.0 ± 190.8
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highly confluent barrier [40]. The current study strongly suggests
that it is not the tight packing of cells in a strong lipid matrix that
provides the barrier properties of the tissue, rather it was the
highly tortuous porous route which provided a challenge for pen-
etration. Using this paradigm to understand the data it is easier
to incorporate the fact that keratin binding to the nail is known
to influence nail penetration. Amorolfine and terbinafine have been
reported to bind strongly to keratin [41]. This type of keratin bind-
ing would be unlikely to change significantly when pores were
opened by the disease and hence it would be unlikely that the dis-
ease would change the passage of the hydrophobic molecules.3.2. Nail barrier properties
The diseased state had no influence on TOWL (Table 1), i.e., no
significant difference was found (t-test, p > 0.05,) between the
TOWL measurements of healthy and diseased nails. This was a lit-
tle surprising as the diseased nails were known to be more porous
and hence one would expect a great amount of water to be lost
from the nail. When the TOWL values were plotted against thick-
ness for each nail sample there were two clusters of points corre-
sponding to healthy and diseased nails (Fig. 4), however there
was no discernible correlation between the parameters with the
separate clusters observable relating to the increased thickness of
diseased nails. The similar TOWL values of the (thicker) diseased
nails and (thinner) healthy ones could be a result of the greater
porosity of diseased nails which allows a free movement of water
vapour. The TOWL data interpretation noted here matches the pre-
vious reports that have measured TOWL and tissue thicknessFig. 4. TOWL plotted against thickness for both healthy and diseased nails.
Fig. 5. Drug fluxes from the permeation data for caffeine, amorolfine and teracross a number of patient volunteers. For example, Jemec et al.
showed no correlation between these parameters across 21 indi-
viduals [42]. Other previous work, using a gravimetric measure
of water loss, showed that the nail thickness increase seemed to
compensate for the greater porosity when the infection was
acquired in vivo and this normalised the water loss across the dis-
eased and healthy nails [27]. Combining the TOWL data in this
study and the water loss data from the previous work again sup-
ported the notion that the nail thickening was an adaptive change
by the body in response to the infection in order to maintain the
local tissue’s water homeostasis. The previous work that demon-
strated that this nail thickening did not occur when the infection
was induced in vitro again supports this adaptation hypothesis
[27].3.3. Penetration route
The nail plate thickness was expected to influence ungual per-
meation and it influenced to some extent the pathlength of tissue
through which the molecules had to travel in order to pass the nail,
and so this was explored further by plotting drug flux for each nail
sample against its thickness and the Pearson correlation coeffi-
cients (r values) were calculated (Fig. 5). An influence of nail thick-
ness on permeant flux was only observed for caffeine with r being
0.92 and 0.76 for healthy and diseased nails respectively, with
the correlation being statistically significant (p < 0.05) for the
healthy nails only. The lack of any kind of correlation for the terbi-
nafine and amorolfine (p > 0.05) data supported the notion that
keratin binding plays a greater role in their permeation across nail
rather than the nail acting as a simple diffusional barrier. When the
drug flux was plotted against TOWL for each nail, a significant cor-
relation (p < 0.05) was observed for caffeine permeation, with r val-
ues of 0.99 and 0.89 for healthy and diseased nails respectively
with no correlation observable for terbinafine or amorolfine
(Fig. 6). The strength of this correlation was thought to be an indi-
cation that the hydrophilic caffeine passed through healthy and
diseased nails via the same diffusional pathway as water and that
TOWL may provide useful insight into the nail barrier to the per-
meation of small hydrophilic molecules. In contrast it does not
appear to be useful in explaining the nature of the nail barrier to
hydrophobic molecules. Moreover as TOWL did not vary with dis-
ease state despite the structural changes that this produces, it is
suggested that TOWL cannot be used as an indication of nail plate
integrity and the barrier in general, in contrast to the equivalent
transepidermal water loss (TEWL) which is often used as a mea-
sure of skin integrity and barrier function. This again demonstrates
that the skin and the nail act as very different barriers. The charac-
teristics of an onychomycosis infected nail may differ in vivo in
comparison with when it is used in an ex vivo experimental design,
for example as a result of differences in nail hydration. As such care
should be taken in directly applying these findings to the clinical
situation. In addition it would be beneficial to confirm thesebinafine across healthy and diseased nails plotted against nail thickness.
Fig. 6. Drug fluxes from the permeation data for caffeine, terbinafine and amorolfine across healthy and diseased nails plotted against nail TOWL value.
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of molecules. However the lack of an appropriate preclinical in vivo
model for ungual permeation means that currently, the ex vivo use
of healthy, and the more difficult to obtain diseased nail tissue, is
considered to be the most suitable model for investigating drug
permeation across the nail and understanding the nature of the
nail barrier [43].4. Conclusion
This report appears to be the first published study to systemat-
ically investigate the ungual permeation of anti-onychomycotic
agents through diseased nails donated by patient volunteers. This
was made possible using the specialised ChubTur diffusion cell
which is capable of holding a small sample of the diseased nail
plate obtained from patient volunteers during an ex vivo perme-
ation experiment. Whilst ungual permeation of the small hydro-
philic molecule caffeine was greatly increased in diseased nails
there was no change in the fluxes and lag times of the hydrophobic
antifungals terbinafine and amorolfine. Thus the commonly held
assumption that diseased nail is more permeable than its healthy
equivalent appears only to be true when applying a small and
hydrophilic molecule to the nail surface. This is unfortunate when
it is considered that most drugs marketed for the topical treatment
of onychomycosis are lipophilic in nature and thus it is not surpris-
ing that such products have long treatment times. Although an
effort is being made in developing new chemical entities (e.g. tava-
borole Mwt. 152.0 and cLogP 1.24) with better properties for
ungual penetration, this study suggests that the focus for the
future should be on drugs that are even more hydrophilic so that
they can take advantage of the decreased barrier of the diseased
nail.
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